Aakash Desai: New T-cell Engager Showing Promise in DLL3+ Lung and Neuroendocrine Cancers
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“New T-cell engager showing promise in DLL3+ lung and neuroendocrine cancers!
Phase 1 results of obrixtamig (BI 764532), a DLL3/CD3 bispecific IgG-like T-cell engager, presented in JCO. Boehringer Ingelheim
This first-in-human study included patients with SCLC, LCNEC, and epNEC, most of whom were heavily pretreated (72% ≥2 prior lines).
Key results from Regimens B2/B3 (step-up followed by target dose):
- ORR: 28% overall
- LCNEC ORR: 70%
- Median DoR: 8.5 months
- CRS: Mostly low-grade, early, and reversible
- MTD not reached across 168 patients
This data validates DLL3 as a compelling target, and obrixtamig as a potential new therapy in a space with few effective options!”
Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus M. Sayehli, Edurne Arriola, Jürgen Wolf, Liza C. Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern
Read the Full Article.
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023